Stock Events

Stock Events

Aptose Biosciences 

€1.4700
77
+€0.12+8.89% Friday 13:32

Statistics

Day High
1.47
Day Low
1.44
52W High
1.52
52W Low
0.905
Volume
0
Avg. Volume
35
Mkt Cap
3.75M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

4AugExpected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
-2.99
-2.64
-2.3
-1.95
Expected EPS
N/A
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Agios Pharmaceuticals
AGIO
Mkt Cap1.98B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, directly competing in the oncology and hematology space similar to Aptose's focus.
Incyte
INCY
Mkt Cap25.69B
Incyte Corporation specializes in oncology products, directly competing with Aptose in developing treatments for hematologic cancers.
TG Therapeutics
TGTX
Mkt Cap8.57B
TG Therapeutics focuses on developing treatments for B-cell malignancies and autoimmune diseases, overlapping with Aptose's research in hematologic malignancies.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a large biopharmaceutical company with a strong presence in oncology and hematology, making it a direct competitor.
Novartis
NVS
Mkt Cap304.1B
Novartis AG, with its extensive portfolio in healthcare, including treatments for cancer, competes in the same market as Aptose, especially in oncology.
AMGEN
AMGN
Mkt Cap236.38B
Amgen focuses on human therapeutics, including oncology/hematology, which puts it in direct competition with Aptose's cancer research efforts.
Karyopharm Therapeutics
KPTI
Mkt Cap40.6M
Karyopharm Therapeutics is involved in the discovery and development of drugs for the treatment of cancer, including hematologic malignancies, similar to Aptose's focus.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie has a strong portfolio in oncology, including treatments for hematologic cancers, making it a competitor in the same therapeutic area as Aptose.

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Show more...
CEO
ISIN
CA03835T4081

Listings

STU
DE
LTIA.STU
US
APTOF

0 Comments

Share your thoughts

FAQ

What is Aptose Biosciences stock price today?▼
The current price of LTI0.STU is €1.47 EUR — it has increased by +8.89% in the past 24 hours. Watch Aptose Biosciences stock price performance more closely on the chart.
What is Aptose Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Aptose Biosciences stocks are traded under the ticker LTI0.STU.
Is Aptose Biosciences stock price growing?▼
LTI0.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Aptose Biosciences has showed a +45.54% increase.
What is Aptose Biosciences market cap?▼
Today Aptose Biosciences has the market capitalization of 3.75M
In which sector is Aptose Biosciences located?▼
Aptose Biosciences operates in the Other sector.
When did Aptose Biosciences complete a stock split?▼
Aptose Biosciences has not had any recent stock splits.